CRL-2558 PL45 人导管腺癌细胞

CRL-2558 PL45 人导管腺癌细胞 的详细介绍
CRL-2558 PL45 人导管腺癌细胞

ATCC® Number:	CRL-2558™	Price:	$329.00
Designations: PL45 Depositors: SE Kern Biosafety Level: 1 Shipped: frozen Medium & Serum: See Propagation Growth Properties: adherent Organism: Homo sapiens (human) Morphology: epithelial Source: Organ: pancreas Disease: ductal adenocarcinoma Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. CRL-2558 PL45 人导管腺癌细胞 Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 + DNA Profile (STR): Amelogenin: X CSF1PO: 12 D13S317: 12 D16S539: 9,12 D5S818: 13 D7S820: 8,9 THO1: 6,9.3 TPOX: 11 vWA: 16 Age: adult Gender: male Ethnicity: White Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656] This gene is transcriptionally silenced and methylated in PL45 cells. PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene. Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656] The line expresses wild-type DPC4 and BRCA2 genes. The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine. The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547). Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C Subculturing: Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37°C. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended Medium Renewal: Every 2 to 3 days Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002 recommended serum:ATCC 30-2020 derived from same individual:ATCC CRL-2547 References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 50656: Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32, 1994. PubMed: 7726912 51521: Su GH, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98: 3254-3257, 2001. PubMed: 11248065

ATCC® Number: CRL-2558™ Price: $329.00
Designations: PL45
Depositors: SE Kern
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas
Disease: ductal adenocarcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 +
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 9,12
D5S818: 13
D7S820: 8,9
THO1: 6,9.3
TPOX: 11
vWA: 16
Age: adult
Gender: male
Ethnicity: White
Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin.
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656]
This gene is transcriptionally silenced and methylated in PL45 cells.
PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene.
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656]
The line expresses wild-type DPC4 and BRCA2 genes.
The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine.
The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.Add appropriate aliquots of the cell suspension to new culture vessels.
6.Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC
上海复祥生物提供 ATCC 细胞|细胞系|细胞株|肿瘤细胞|细胞|贴壁细胞|悬浮细胞|,细胞库管理规范,提供的细胞株背景清楚,提供参考文献和优培养条件,网站上有细胞照片,联系邮箱xiangfbio@163.com.详情请登陆http://www.xiangbio.com/欢迎各位老师来电咨询!
iec-6 大鼠小肠隐窝上皮细胞
马-达二氏犬肾细胞系 MDCK (NBL-2) CRL-34
鸭子胚胎成纤维细胞　 Duck embryo　 CCL-141
小鼠胚胎成纤维细胞 3T3-L1 CCL-173
人结肠直肠腺癌 COLO 320DM CCL-220
人结肠直肠腺癌 NCI-H508 CRL-253
人结肠直肠腺癌 COLO 320HSR CCL-220.1
人B淋巴细胞 Ramos（RA1） CRL-1596
人淋巴母细胞 T2(174×CEM.T2) CRL-1992
大鼠心肌细胞 H9C2(2-1) CRL-1446
猪鼻甲黏膜成纤维细胞 PT-K75 CRL-2528
小鼠癌细胞 LTPA CRL-2389
大鼠癌细胞 DSL-6A/C1 CRL-2132
小鼠瘤B淋巴细胞 SP2/MIL-6 CRL-2016
大鼠脑间质细胞 DI TNC1 CRL-2005
小鼠肌原细胞 C2C12 CRL-1772
鹌鹑纤维肉瘤细胞 QT6 CRL-1708
大鼠回肠细胞 IEC-18 CRL-1589
非洲绿猴肾细胞 VERO C1008 [Vero 76, clone E6, Vero E6] CRL-1586
人成纤维细胞 Hs 738.St/Int CRL-7869
人正常前列腺上皮细胞 WPE-int CRL-2888
人正常前列腺成肌纤维细胞 WPMY-1 CRL-2854
人导管腺癌细胞 PL45 CRL-2558
人癌细胞 Panc 05.04 CRL-2557
人癌细胞 Panc 04.03 CRL-2555
人癌细胞 Panc 02.03 CRL-2553
人癌细胞 Panc 08.13 CRL-2551
人癌细胞 Panc 03.27 CRL-2549
人癌细胞 Panc 10.05 CRL-2547
人肝癌细胞 SNU-398 CRL-2233
人成神经瘤细胞- SK-N-DZ CRL-2149
人癌细胞 HPAC CRL-2119
人癌细胞 HPAF-II CRL-1997
人黑色素瘤细胞 A375.S2 CRL-1872
人脐静脉内皮细胞 HUV-EC-C CRL-1730
人黑素瘤细胞 WM-266-4 CRL-1676
人膀胱癌细胞 HT-1376 CRL-1472
人正常前列腺上皮细胞 RWPE-2 CRL-11610
人正常前列腺上皮细胞 RWPE-1 CRL-11609
鸡胚胎成纤维细胞 UMNSAH/DF-1 CRL-12203
人乳腺癌细胞 MDA-MB-231 HTB-26
小鼠巨噬细胞 RAW 264.7 TIB-71
人横纹肌肉瘤细胞 A-204 HTB-82
人癌细胞 Capan-2 HTB-80
人癌细胞 Capan-1 HTB-79
人乳腺导管癌细胞 MDA-MB-435S HTB-129
人胃癌细胞 Hs 746T HTB-135
人肺腺癌细胞 NCI-H441 [H441] HTB-174
人瘤细胞 U266 TIB-196
人结肠癌细胞 NCI-H716 [H716] CCL-251
人多形性恶性胶质瘤 T98G [T98-G] CRL-1690
人神经母细胞瘤细胞 BE(2)-C CRL-2268
人肾透明细胞癌细胞 Caki-2 HTB-47
人皮肤成纤维细胞 Hs 865.Sk CRL-7601
CA46 人淋巴瘤细胞系
CRL-5826 NCI-H226 人肺鳞癌细胞系
Tca-8113 人舌鳞癌细胞
MA-891 小鼠乳腺癌高转移细胞
U14 小鼠宫颈癌细胞
CRL-9518 L5178Y 小鼠淋巴瘤细胞
HTB-112 HEC-1-A 人子宫内膜腺癌细胞
HTB-113 HEC-1-B 人子宫内膜腺癌细胞
AN3 CA 人子宫内膜腺癌细胞
ROS1728 大鼠成骨细胞
CRL-6323 B16F1 小鼠黑色素瘤细胞
HTB-58 SK-MES-1 人肺鳞癌细胞
CCL-127 IMR-32 人神经母细胞瘤细胞
HTB-79 Capan-2 人癌细胞
BALL-1 人B淋巴细胞急性白血病细胞
CRL-2922 Eayh926 人脐静脉细胞融合细胞
WB-F344 大鼠肝干细胞
CRL-1715 TM4 正常小鼠睾丸细胞
CRL-2539 4T1 小鼠乳腺癌细胞
CRL-1442 BRL-3A 大鼠肝细胞
BRL 大鼠肝细胞
RSC96大鼠雪旺细胞
Isk 人子宫内膜癌细胞
HTB-113 hec-1-b 人子宫内膜腺癌细胞
PLA-802?人恶性横纹肌肉瘤
Pt-K2 袋鼠肾细胞
BS-C-1 非洲绿猴肾细胞
A498人肾癌细胞
3AO人卵巢癌细胞
iec-6 大鼠小肠隐窝上皮细胞
u87MG 人脑星形胶质母细胞瘤
Renca 小鼠肾癌细胞
nci-h929 瘤细胞
P388小鼠白血病细胞
opm-2 瘤细胞
MDA-MB-435 人乳腺癌高转移细胞
KU812 人外周血嗜碱性白细胞
NIH:OVCAR-3 人卵巢癌细胞
SW 1990人癌细胞系
S180人结肠腺癌细胞
HuTu-80十二指肠腺癌
RL95-2 人子宫内腺癌细胞
NCI-H446 人小细胞肺癌细胞
MSTO-211H 人肺癌细胞
H4-Ⅱe 大鼠肝癌细胞系
HLF 人肺成纤维样细胞
LS 180人结肠腺癌细胞
HuTu-80十一指肠腺癌
ST猪睾丸细胞系
REH人急性非B非T淋巴细胞白血病
NCI-H520 人肺鳞癌细胞
RKO 人结肠腺癌细胞
293A 人胚肾细胞
RK-13 兔肾细胞系